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Summary:  
Mitochondrial ADP/ATP carriers transport ADP into the mitochondrial matrix for ATP 
synthesis, and ATP out to fuel the cell, by cycling between cytoplasmic-open and matrix-open 
states. The structure of the cytoplasmic-open state is known, but it has proved difficult to 
understand the transport mechanism in the absence of one in the matrix-open state. Here, 
we describe the structure of the matrix-open state locked by bongkrekic acid bound in the 
ADP/ATP-binding site at the bottom of the central cavity. The cytoplasmic side of the carrier 
is closed by a salt bridge network, braced by tyrosines, and conserved hydrophobic residues. 
Manuscript
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Glycine and small amino acid residues allow close-packing of helices on the matrix side. 
Uniquely, the carrier switches between states by rotation of its three domains about a 
fulcrum provided by the substrate-binding site. Since these features are highly conserved, this 
mechanism is likely to apply to the whole mitochondrial carrier family. 
 
Keywords: adenine nucleotide translocator; adenine nucleotide translocase; bongkrekate; 
cardiolipin; induced fit; transport mechanism; bioenergetics; mitochondria; alternating 
access mechanism 
 
Introduction:  
Solute transport across the impermeable mitochondrial inner membrane is essential for the 
function and survival of eukaryotic cells. The majority of these transport steps are catalysed 
by membrane proteins of the mitochondrial carrier family (Monne and Palmieri, 2014). The 
archetypal member of the family, the ADP/ATP carrier, performs the vital role of transporting 
ADP into the mitochondrial matrix and ATP out of the mitochondrion to maintain high 
cytosolic ATP concentrations for energy-requiring reactions (Kunji et al., 2016). Every day, this 
carrier transports our own body weight in ADP and ATP, recycling each ATP molecule more 
than a thousand times. The carrier cycles between the cytoplasmic-open state (c-state), which 
can be trapped by the membrane-impermeable toxic inhibitor carboxyatractyloside (CATR) 
(Vignais et al., 1973), and the matrix-open state (m-state), which is locked by the membrane-
permeable bongkrekic acid (BKA) (Erdelt et al., 1972; Henderson and Lardy, 1970). BKA is a 
polyunsaturated methoxy tricarboxylic acid polyketide produced by Burkholderia gladioli 
pathological variant cocovenenans (Bruijn et al., 1973; van Veen and Mertens, 1934). Over 
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2,000 cases of human fatality from BKA poisoning have been reported in Indonesia, China, 
and Mozambique since 1950, due to contamination of corn or coconut products (tempe 
bongkrek) (Anwar et al., 2017; Falconer et al., 2017). 
 
Mitochondrial carriers consist of three homologous sequence repeats of about 100 amino 
acids (Saraste and Walker, 1982), which form a three-fold pseudosymmetrical structure with 
the translocation path through the centre of the molecule (Kunji and Harding, 2003). The first 
atomic structure of the CATR-inhibited bovine ADP/ATP carrier (Pebay-Peyroula et al., 2003) 
was followed by those of yeast ADP/ATP carriers in the same state (Ruprecht et al., 2014). 
Each sequence repeat forms a domain, comprising an odd-numbered transmembrane helix 
(H1, H3 or H5), a loop containing a short matrix helix lying parallel to the membrane (h12, h34 
or h56), and an even-numbered transmembrane helix (H2, H4, or H6) (Pebay-Peyroula et al., 
2003). In the C-terminal region of each odd-numbered transmembrane helix, a conserved 
signature motif Px[DE]xx[KR] is found (Pebay-Peyroula et al., 2003). The proline residues of 
this motif are located at pronounced kinks in the odd-numbered helices, giving them an L-
shape. Consequently, these helices come together on the matrix side, where the charged 
residues of the three motifs form the matrix salt bridge network, closing the central cavity to 
the mitochondrial matrix in the c-state (Pebay-Peyroula et al., 2003). 
 
Nucleotides are amongst the largest solutes to cross biological membranes, yet mitochondrial 
carrier proteins are relatively small. Transport must therefore involve profound 
conformational changes, which nevertheless must prevent proton leak across the 
mitochondrial inner membrane. Until now, the molecular mechanism by which mitochondrial 
carriers transport has not been established. However, some sequence features required for 
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a transport mechanism have been identified. First, a consensus substrate-binding site has 
been proposed in the central cavity (Dehez et al., 2008; Robinson and Kunji, 2006; Robinson 
et al., 2008; Wang and Tajkhorshid, 2008). Second, a conserved motif [YF][DE]xx[KR] was 
identified on the even-numbered helices, the charged residues of which likely form a 
cytoplasmic salt bridge network in the m-state (King et al., 2016; Robinson et al., 2008; 
Ruprecht et al., 2014). It has been proposed that substrate binding leads to the 
interconversion of states by disruption and formation of the cytoplasmic and matrix salt 
bridge networks, opening and closing the carrier to either side of the membrane (Kunji et al., 
2016; Robinson and Kunji, 2006; Ruprecht et al., 2014). Here, we have determined the 
structure of the ADP/ATP carrier inhibited by BKA, which represents the first structure of a 
carrier in an m-state conformation and reveals the molecular mechanism of transport utilised 
by mitochondrial carrier proteins. 
 
Results: 
A nanobody-stabilized BKA-inhibited ADP/ATP carrier structure 
Mitochondrial carriers are highly dynamic proteins, and the m-state is known to be unstable 
in detergent solution (Crichton et al., 2015), which has hampered structure determination. 
To solve these problems, we targeted the BKA-inhibited ADP/ATP carrier from the moderately 
thermophilic fungus Thermothelomyces thermophila (TtAac, Fig. S1), carrying a single 
mutation (Q302K) in the cytoplasmic network that increases the thermal stability (King et al., 
2016). Furthermore, we selected a nanobody against this state, and crystallized the complex 
(see STAR Methods for details). TtAac has 75% sequence identity to Saccharomyces cerevisiae 
ScAac2 and ScAac3, and 51% sequence identity to bovine Aac1p, the structures of which have 
been determined in the CATR-inhibited state (Pebay-Peyroula et al., 2003; Ruprecht et al., 
 5 
2014). Crystals diffracted anisotropically to 3.3 Å (Table S1, TtAac-Nb crystal), enabling 
structure determination (Fig. S1). 
 
The crystal is composed of alternating layers of carrier and nanobody molecules, with crystal 
contacts between the carrier layers being mediated by the nanobodies (Fig. S2). The carrier 
consists of six transmembrane helices surrounding a central cavity (Fig. 1). The structural fold 
has the characteristic three domain structure of this protein family (Fig. 1B). The matrix salt-
bridge network (E37, K40, D142, R145, D242 and R245) and cytoplasmic salt-bridge network 
(D101, K104, D205, K208, D299 and K302) flank the central proposed substrate-binding site 
(K30, R88, G192, I193, Y196, S238 and R287) (Fig. 1C). The carrier binds one molecule of BKA 
and several cardiolipin molecules, which bind to positively-charged pockets due to the N-
terminal dipoles of the matrix and even-numbered transmembrane helices (Fig. S3). 
 
Comparison of the BKA-inhibited carrier structure with the CATR-inhibited c-state structure 
of the homologous S. cerevisiae ADP/ATP carrier Aac2p (ScAac2, PDB: 4C9H) reveals a 
profound conformational change (Fig. 2). The BKA-inhibited m-state has a central cavity open 
to the mitochondrial matrix side of the membrane, with the matrix helices rotated outwards 
(Figs. 1 and 2). In the m-state, the cavity is closed to the cytoplasmic side of the membrane 
by a cluster of residues that includes those of the cytoplasmic salt bridge network (Figs. 1C 
and S4). In the c-state, which is open to the cytoplasmic side, the cytoplasmic network 
residues are far apart, whereas the matrix salt bridge network residues are interacting, 
helping to close the carrier on the matrix side (Pebay-Peyroula et al., 2003; Ruprecht et al., 
2014). Solvent accessibility calculations map out the geometry of the central cavity in both 
states and reveal that each state has an approximately 15 Å thick gate, closing off access to 
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the central cavity from one side of the membrane and thus preventing proton leak (Fig. 2A 
and 2B). The consensus residues of the proposed substrate-binding site (Kunji et al., 2016), 
which we confirm are essential for the function of TtAac (Fig. S5), are accessible for substrate 
binding in both states. This observation provides structural support for the single-binding 
center gated pore hypothesis (Klingenberg, 1979), which is essentially an alternating access 
model (Jardetzky, 1966). Comparing surface representations shows the dramatically different 
shapes of the two states (Fig. 2C-F). Viewed from the matrix side, the m-state has a strong 
positively charged central cavity around the substrate-binding site, primed for binding 
negatively charged ATP (Fig. 2C), whereas access to the cavity is closed in the c-state with a 
predominantly neutral surface (Fig. 2D). Viewed from the intermembrane space, the cavity is 
closed in the m-state, with a predominantly neutral surface, except for a small positively 
charged patch (Fig. 2E), whereas a positively-charged cavity is visible in the c-state (Fig. 2F). 
 
A gate blocks access from the cytoplasmic side 
The structure reveals that in the m-state, the charged residues of the cytoplasmic salt bridge 
network, part of the conserved [YF][DE]xx[KR] motif (Fig. S4), come into close proximity and 
form electrostatic interactions, linking the even-numbered transmembrane helices of each 
domain (Fig. 3A), in agreement with functional data (King et al., 2016). K104 on H2 forms a 
salt bridge with D205 on H4, and K208 on H4 interacts with D299 on H6. K302 on H6, which 
was mutated to stabilize the m-state (King et al., 2016), interacts weakly with D101 on H2. In 
the wild-type carrier, the corresponding residue is Q302, which when modelled in silico is too 
far away to interact with D101 directly (Fig. 3A inset). Close to the salt bridge residues, a highly 
conserved set of tyrosine residues, positioned a turn of helix away from the positively charged 
residues of the network, unexpectedly act as braces for the salt bridges, providing extra inter-
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domain interactions (Figs. 3A and S4). Y204 forms a hydrogen bond with D299, bracing the 
K208/D299 salt bridge. Y298 forms a hydrogen bond with D101, compensating for the weak 
D101/K302 interaction. We call these extra interactions tyrosine braces. ADP/ATP carriers are 
unusual in the mitochondrial carrier family in having a positively charged residue substituting 
for tyrosine on H2 (Fig. S4). Here, R100 forms electrostatic interactions with both D101 (intra-
domain) and D205, bracing the K104/D205 salt bridge in an equivalent way to the tyrosine 
braces. These tyrosine braces, which are part of the highly conserved [YF][DE]xx[KR] motif, 
serve a similar function to the glutamine braces observed for the matrix salt bridge network 
(Ruprecht et al., 2014). The number of these braces vary in different members of the 
mitochondrial carrier family, modulating the interaction energy of the networks (Fig. S4). 
Comparison with the c-state shows that the residues have moved 12-17 Å for the formation 
of the cytoplasmic network (Fig. 3B). 
 
We have previously studied the effect of cytoplasmic salt bridge network mutations on the 
thermal stability of the BKA-inhibited carrier, showing that these interactions contribute 
significantly to the overall thermal stability of the protein in the matrix state (King et al., 2016). 
The structure reveals that there are few inter-domain interactions other than those of the 
cytoplasmic salt-bridge network and brace residues, which is an important functional feature 
of this highly dynamic protein. Therefore, the relative network strength correlates well with 
the overall stability of the protein. Here, we extend our analysis to include the tyrosine brace 
interactions (Fig. 3C). In the BKA-inhibited state, mutation of R100 and Y204 significantly 
reduces the thermal stability compared to the wild-type protein, consistent with these 
residues forming a brace that stabilizes the m-state. Y298F did not have a significant effect on 
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thermal stability of the BKA-inhibited state compared to the wild-type, consistent with Y298 
forming the weakest link in the network. 
 
Previously, the effect of substrate-binding and salt bridge formation and disruption on the 
transport rate was analysed by treating the carrier as a nanomachine moving stochastically 
between the m-state and c-state under the influence of thermal energy (Springett et al., 
2017). This computational analysis shows that maximum transport occurs when the 
interaction energies of the cytoplasmic network, matrix network and substrate binding are 
approximately equal. As a consequence, the analysis predicted that interactions in addition 
to the cytoplasmic salt bridge network should stabilise the matrix state. The current structure 
reveals that the tyrosine braces provide these additional interactions, resulting in the 
cytoplasmic and matrix networks having similar numbers of polar interactions (Fig. 3D). The 
effect of mutations of the cytoplasmic salt bridge network and braces on the transport rate 
was investigated (Fig. 3E). Mutations of residues involved in electrostatic interactions (R100, 
K104 and K208) had the greatest effect on the transport rate, followed by Y204. Mutations of 
Q302 and Y298 had only a mild effect. Thus, mutations of the strongest links in the 
cytoplasmic network have the largest effects upon transport and thermal stability, as 
expected from the structure of the cytoplasmic network in the m-state and the computational 
model. 
 
Just beneath the tyrosine brace residues, there are other aromatic or bulky hydrophobic 
residues (F97, F201 and L295) that come together to form a hydrophobic plug. These residues 
converge when the carrier is in the m-state (Fig. 3F), but are separate in the c-state (Fig. 3G). 
The residues of the hydrophobic plug together with the cytoplasmic salt bridge network and 
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tyrosine braces form the cytoplasmic gate, which is highly conserved in all members of the 
mitochondrial carrier family, highlighting their important role in the transport cycle (Fig. S4). 
Another set of residues, which are variable within the mitochondrial carrier family, form the 
ceiling of the substrate-binding site (N96, Y200 and V294). 
 
Bongkrekic acid is a conformation-specific competitive inhibitor 
Electron density maps calculated following molecular replacement revealed extra density in 
the cavity, not accounted for by protein atoms. As model building and refinement progressed, 
this density could be modelled as the inhibitor BKA (Figs. 1, 4, S1C and S6A). 
 
BKA inhibits the carrier by binding deeply and asymmetrically within the central cavity (Figs. 
1 and 4). The polyunsaturated backbone of the inhibitor forms a horseshoe shape, allowing 
the carboxylate groups at either end of the inhibitor to interact with key amino acids that lie 
close together in space. BKA interacts directly with all residues of the putative substrate-
binding site (Kunji et al., 2016), forming electrostatic interactions with K30 and R88, and a 
hydrogen bond to Y196 (Fig. 4B and C). The carboxymethyl and distal carboxylate group at 
either end of the inhibitor both form electrostatic interactions with R197, and additional 
hydrogen bonds are formed to N96 and Y89. The large number of interactions formed 
between the inhibitor and protein explains the tight binding of BKA (Fig. S6B) (Klingenberg et 
al., 1983). ATP can be docked into the binding site (Fig. S6C), with the phosphate groups 
interacting with K30, R88 and R287, and the adenine ring sitting in a hydrophobic pocket 
formed by G192, I193, Y196 and S238, and potentially forming aromatic stacking interactions 
with the tyrosine, in agreement with previous work based on the c-state (Kunji et al., 2016). 
Comparison of the ATP and BKA binding geometries shows that the dicarboxylate end of BKA 
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mimics the phosphate groups of ATP, while the polyunsaturated backbone of the inhibitor 
acts as a partial mimic of the adenine ring of the substrate, sitting in the hydrophobic pocket 
(Fig. S6C and D). The position and steric bulk of the polyunsaturated backbone would prevent 
the inhibitor from binding to the c-state. BKA thus shows the characteristics of a 
conformation-specific competitive inhibitor. 
 
Random mutagenesis of the related ScAac2 has produced mutant strains of yeast that are 
resistant to BKA but can still grow on non-fermentable carbon sources, which requires the 
carrier to be functional (Zeman et al., 2003). Four mutations were identified, and three of 
them are within the observed BKA-binding site (Y97C, L142S and G298S, equivalent to Y89, 
L135 and G291 in TtAac). These residues are in van der Waals contact with BKA (Fig. 4D), and 
the Y97C mutation would remove a hydrogen bond to BKA. The fourth mutation lies within 
the GxxxG motif, described below (Cappello et al., 2007). Interestingly, the key residues 
involved in substrate-binding are not affected by these mutations, explaining why transport 
could still occur. The agreement between the position of mutations and the BKA-binding site 
confirms that the observed BKA binding pose reflects that found in the native membrane. In 
another approach, the role of residues near the cavity in binding BKA had been assessed prior 
to structure determination by comparing the thermostability of the BKA-inhibited wild-type 
with those of BKA-inhibited mutants (Fig. S6E). Mutating key residues involved in BKA-binding 
(e.g. K30, R88, N96, I193, Y196, R197) reduced the stabilizing effect of BKA binding observed 
in the wild-type protein, consistent with weaker binding of the inhibitor. Mutagenesis of R287 
or S238, which form weak van der Waals interactions with BKA rather than polar interactions, 
did not significantly reduce the thermal stability of the inhibited carrier. The thermal stability 
of the mutants in the presence of CATR confirms that they are folded correctly (Fig. S6F). 
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Mutation of residues that are known to interact with CATR in the closely-related ScAac2 
(Ruprecht et al., 2014), has a strong effect on thermal stability of the CATR-inhibited state, 
whereas a weaker effect is seen for those that are further away, confirming that 
thermostability assays can be used to map inhibitor-binding sites. 
 
GxxxG and πxxxπ motifs allow close packing of helices on the cytoplasmic side 
In the BKA-inhibited state, transmembrane helices are packed closely on the cytoplasmic side 
of the membrane, helping to form the cytoplasmic gate. This is facilitated by amino acids with 
small side chains lying at the intra-domain interfaces, which include residues of the highly 
conserved GxxxG motif on the odd-numbered helices (Figs. 5 and S4), for example G127 and 
G131 on H3. Other conserved small residues are found on the adjacent even-numbered 
helices, for example G198 and G202 on H4, which we call the πxxxπ motif after the one letter 
code for small amino acids (Figs. 5B and S4). A similar arrangement is seen in domains 1 and 
3 (Fig. 5A and C). The requirement for residues with small side chains at these positions 
explains their conservation, which was not apparent from the c-state structures (Fig. 5D and 
E). 
 
For the inter-domain interfaces, close-packing of helices at the cytoplasmic side is facilitated 
by conserved small amino acids on the odd-numbered transmembrane helices, for example 
A130 on H3 of domain 2. Residues on the even-numbered helices do not point directly at the 
interface but face the lipid bilayer (L95 or F99) or cavity (N96, R100), hence larger side-chains 
can be tolerated here. A similar arrangement is observed in all three inter-domain interfaces 
in the m-state structure and also in the c-state structures (Ruprecht et al., 2014). 
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Conformational changes between c- and m-states 
Comparison of the structures of the three domains in BKA- and CATR-inhibited carriers (Fig. 
6A-C) reveals that about 80% of the domain structure is conserved between the two states, 
which we call the core element, comprising the odd-numbered, matrix, linker and one-third 
of the even-numbered helices. In particular, there are no major changes to the kink angle 
around the proline residues of the signature motif, consistent with the notion that the kink is 
stabilized by interactions within the domain (Ruprecht et al., 2014). The proposal that the 
conformational change may involve these proline residues acting as hinges during transport, 
with the odd-numbered helices straightening during the transition to the m-state (Pebay-
Peyroula et al., 2003), is not supported by the current structure. There is, however, a 
significant and unexpected movement of the C-terminal region of the even-numbered helices 
in all three domains towards the central axis from the c- to the m-state. Thus, the domains do 
not move as single rigid bodies and are more dynamic than originally anticipated (Ruprecht 
et al., 2014). In the m-state, the even-numbered helices kink at R88 (H2), G192 (H4) and R287 
(H6), which are key amino acids predicted to be involved in substrate-binding, called the 
contact points of the substrate-binding site (Kunji and Robinson, 2006; Robinson and Kunji, 
2006). The inward movement of these helical regions (comprising the even-numbered helices 
from the contact point to the C-terminal end), which we call the gate elements, contributes 
to bringing the residues of the cytoplasmic network together. Conformational change from 
the c- to m-state must involve rigid-body rotations of the core elements to open the central 
cavity to the mitochondrial matrix, and inward movements of the gate elements, closing the 
central cavity to the intermembrane space. 
 
Inhibitor-binding is accompanied by induced fit 
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It has been proposed that the inhibitors CATR and BKA induce structural perturbations of the 
c- and m-states, because the inhibitors have larger molecular volumes than the substrates, 
and maximise their interactions with the protein, thus increasing their binding affinity 
(Klingenberg, 2008). The inhibited states have therefore been called abortive states, not lying 
directly on the transport cycle pathway. Comparing the structures binding either inhibitor 
allows us to investigate the structural consequences of inhibition. 
 
We initially analysed the domain structures. For the CATR-inhibited carriers, whilst most of 
the domain structure is conserved, there are noticeable deviations in the positions of the C-
terminal end of H2 and N-terminal end of H3 (Fig. 6D). The structures of the individual 
domains in the BKA-inhibited state superpose well, indicating that the inhibitor has not 
perturbed the structures of the domains themselves (Fig. 6E). 
 
To further understand the consequences of CATR binding, we have taken the core and gate 
elements from the BKA-inhibited structure and superposed them on the CATR-inhibited 
structure (Fig. 6F). Core elements 1 and 3 (from domains 1 and 3) align very well, with RMSDs 
of 0.97 and 1.16 Å for backbone atoms, respectively (Fig. 6 A and C). However, core element 
2 does not align well, with an RMSD of 2.25 Å for backbone atoms (Fig. 6 B). Fitting core 
element 2 with outlier rejection revealed that while most of the structure fits well, there is a 
deviation at the N-terminal end of H3, due to change in the kink angle at the Pro of the 
signature motif (from 76° in the CATR-inhibited state to 43.0° in the BKA-inhibited state). 
When aligning the gate elements, H4 and H6 aligned well (backbone RMSDs of 0.95 and 0.85 
Å, respectively), but H2 did not (backbone RMSD of 1.76 Å). Closer inspection found that this 
misalignment is due to the helix of the BKA-inhibited structure being straight, whereas that 
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of the CATR-inhibited structure is kinked at Phe107 in CATR-inhibited ScAac2 (Phe99 in TtAac). 
This kink is caused by Lys108 interacting with the two sulphate groups of CATR, pulling H2 
down and bringing the C-terminal end close to the end of H3, which is consequently displaced 
as well (Fig. 6G). The deviations in the positions of H2 and H3 observed here are consistent 
with those seen when comparing the CATR-inhibited domains alone (Fig. 6D). Therefore, the 
action of CATR is twofold – first, it acts as a competitive inhibitor by binding to the substrate-
binding site, and second, it induces a structural change in H2 and H3 that locks the carrier in 
an abortive state.  
 
A noticeable difference between the BKA- and CATR-inhibited states is that the CATR-
inhibited state is highly symmetrical, in agreement with the presence of three homologous 
sequence repeats, whereas the BKA-inhibited state is three-fold pseudosymmetric at the 
cytoplasmic side, but somewhat asymmetrical at the matrix side. To investigate the cause, we 
symmetrised the BKA-inhibited structure, whilst treating the domains as rigid bodies (Fig. 6H), 
in agreement with our analysis of the domain structures (Fig. 6E). Comparing the two 
structures, the positions of domains 2 and 3 are similar, but domain 1 is displaced towards 
the matrix side. In agreement, the cardiolipin-binding site between domains 2 and 3 is 
maintained in the BKA-inhibited structure, with good electron density present for the lipid 
(cdl 802), but the sites between domains 1 and 3 and domains 1 and 2 are disrupted (Figs. 1 
and S3). To exclude the unlikely possibility that the domain displacement is a consequence of 
crystal packing interactions or the nanobody interacting with H1 (Fig. S2), we solved the 
structure of the BKA-inhibited carrier from a crystal grown without the nanobody, which 
diffracted anisotropically to 3.6 Å resolution (Table S1, TtAac crystal). Although the crystal 
diffracts to lower resolution than the TtAac-Nb crystal, it confirms that the structure of BKA-
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inhibited TtAac is not significantly affected by nanobody binding (Fig. S7). The displacement 
of domain 1 is therefore likely to be due to inhibitor binding, leading to an abortive m-state. 
Closer inspection shows two likely molecular reasons for the abortive state. First, E37 in the 
symmetrised carrier lies in close proximity to negatively charged groups of BKA, so 
electrostatic repulsion may drive domain displacement. Secondly, the molecular volume of 
the inhibitor (443 Å3) is substantially greater than ATP (354 Å3), hence steric repulsion may 
also play a role (Fig. 6I). 
 
This comparison shows that the inhibitors perturb the structure of the protein, in agreement 
with earlier proposals. Both inhibitors occupy the positions where the substrates bind by 
mimicking the biophysical properties rather than the exact chemistry of the substrates and 
by forming multiple interactions that prevent the substrate competing for binding. 
Carboxylate groups of the inhibitors mimic the phosphate groups of the natural substrates. 
Furthermore, the binding itself distorts the structure of this highly dynamic protein, locking it 
in an abortive state that cannot undergo the required conformational changes for transport. 
 
Discussion 
The available structures have revealed the conformational changes undergone by the 
domains. Further insight requires considering these domain changes in the context of the 
whole protein. A morph between the CATR- and BKA-inhibited states does not provide a 
plausible mechanism, because of the absence of an occluded state and clefts in the lipid-
facing part of the carrier. Having gained insight into the nature of inhibitor-induced 
distortions, we can use models of the uninhibited proteins to propose a plausible transport 
mechanism. Since CATR and BKA bind to different states of the protein, we generated a model 
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of the uninhibited c-state from the superposition of the core and gate elements of the BKA-
inhibited structure with the CATR-inhibited structure (Fig. 6F). The uninhibited m-state model 
is the symmetrised model from the BKA-inhibited structure (Fig. 6H). This seems a more 
reasonable approach than modelling the uninhibited m-state from elements of the CATR-
inhibited structure, due to the CATR-induced kink in H2 and displacement of H3. 
 
Superposition of the uninhibited c- and m-states allows us to propose how the domain 
motions affect the overall conformation of the carrier, leading to opening and closing of the 
substrate-binding site to either side of the membrane. The core elements have a rocking 
motion of about 15°, which is essential for opening and closing of the matrix side of the carrier 
(Fig. 7A). The gate elements rotate towards or away from the central pseudosymmetry axis, 
respectively closing or opening access to the substrate-binding site from the intermembrane 
space (Fig. 7A), with the contact points of the binding site acting as pivots (Kunji and Robinson, 
2006; Robinson and Kunji, 2006). The conformational changes are small around the substrate-
binding site but become progressively larger towards either side of the membrane (Fig. 7B), 
indicating that the substrate-binding site acts as a fulcrum. Since the same substrate-binding 
site is accessible from both c- and m-states, and ADP and ATP are chemically related, the same 
process can apply in either direction across the membrane, explaining the known equimolar 
exchange activity. Atoms move predominantly parallel to the membrane, with no significant 
movement perpendicular, consistent with the transmembrane helices moving within the 
plane of the lipid bilayer. We speculate that engagement of the contact point residues with 
the substrate, leading to tighter interactions, drives the inward movement of the gate 
elements and formation of the cytoplasmic network. Concurrently, the cytoplasmic sides of 
the core elements also move inwards, causing the core elements to rock and to open the 
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matrix side. The involvement of all three contact points in substrate-binding makes it likely 
that the movements of the core and gate elements are symmetrical and simultaneous in all 
three domains, which also prevents clashes or gaps appearing in the protein structure. These 
movements lead to a coupled closing of the cytoplasmic side and an opening of the matrix 
side in the transition from c- to m-states, consistent with an alternating-access transport 
mechanism (Fig. 7C-G). The fungal ADP/ATP carriers have an extra turn of α-helix on the 
matrix end of H1, which is a loop in the bovine carrier. This extra turn slides out of the 
translocation pathway when the carrier transitions from the c- to the m-state, allowing 
sufficient access to the binding-site (Fig. 7G). 
 
The uninhibited m-state model has a narrower cavity leading to the substrate binding site 
than that of the c-state (Fig. 7C, F and G). Access of substrate to the m-state binding site is 
likely to be facilitated by thermal energy driving rotamer changes, changing the size of the 
entry. However, the size difference between the cavities in the two states might reflect the 
biophysical requirements for transport of negatively charged nucleotides in the presence of 
a membrane potential. Import of ADP, which has three negative charges, is opposed by the 
membrane potential. Therefore, the carrier has a large water-filled cavity in the c-state to 
shield the substrate from the influence of the membrane potential until it is bound to residues 
of the substrate binding site. The negatively-charged phosphate groups are neutralised by 
interactions with the three positively charged residues of the binding site (Kunji and Robinson, 
2006), facilitating ADP import. The export of ATP, which has four negative charges, is 
stimulated by the membrane potential, which is maximal when shielding by water is minimal, 
explaining the relatively small cavity in the matrix state. Once ATP is bound to the central 
substrate-binding site, a net negative charge remains, which helps to drive export.  
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A morph between the uninhibited c- and m-states (Movie S1) demonstrates these proposals, 
and passes through an occluded state, in which the substrate-binding site is inaccessible from 
either side of the membrane, which is essential for maintenance of the proton motive force 
across the inner mitochondrial membrane. The structure of the BKA-inhibited carrier provides 
the first insight into the structure of the m-state. It shows that the ADP/ATP carrier functions 
as a monomer (Bamber et al., 2007; Kunji and Crichton, 2010; Kunji and Harding, 2003), 
because the conformational changes alter the overall molecular shape profoundly, precluding 
stable interactions between carriers. The carrier has a single substrate-binding site that is 
alternately accessible from either side of the membrane, in agreement with inhibitor 
(Klingenberg, 1979) and sequence analysis (Robinson et al., 2008). The structure 
demonstrates the formation of the cytoplasmic salt bridge network in the m-state, showing 
that formation and disruption of the cytoplasmic and matrix salt bridge networks are key 
features of the transport cycle (King et al., 2016; Robinson et al., 2008; Ruprecht et al., 2014). 
It has also explained all of the conserved sequence features of mitochondrial carriers, 
including the role of bulky hydrophobic residues in forming the cytoplasmic gate, and the role 
of the GxxxG and πxxxπ motifs in the dynamic conformational changes of the inter-helical 
interfaces during the transport cycle. Since these sequence features are conserved, it is likely 
that the proposed mechanism holds for all mitochondrial carriers, which constitute the 
largest solute carrier family in humans. The mechanism is unique amongst transport proteins, 
as it involves coupled rotations of three domains, with each domain undergoing two separate 
rotations, leading to alternating access from opposite sides of the membrane to the 
substrate-binding site. Together with the CATR-inhibited structures, this structure provides a 
framework for further biophysical and structural analysis of the intermediary states of the 
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transport cycle, which will elucidate how substrates drive the conformational changes, and 
how pathological mutations affect transport activity. 
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Main figure titles and legends 
Fig. 1. Overall structure of the bongkrekic acid-inhibited ADP/ATP carrier. (A) The structure 
of TtAac (rainbow cartoon) bound to bongkrekic acid (ball-and-stick with orange carbons) and 
a nanobody (Nb, wheat cartoon). Cardiolipin molecules associated with the carrier are shown 
as sticks (gray carbons) and a PEG molecule is shown in ball-and-stick representation (gray 
carbons). (B) The carrier protein viewed from the membrane (top), with domains 1, 2 and 3 
colored in blue, yellow and red, respectively, and from the mitochondrial matrix side 
(bottom). Transmembrane helices (H1 to H6) and matrix helices (h12, h34, h56) are labelled. 
(C) The BKA-inhibited carrier viewed from the membrane with key functional elements 
highlighted. Residues of the substrate-binding site are shown as sticks with green carbons. 
Positively-charged (blue carbons) and negatively-charged (red carbons) residues of the 
cytoplasmic and matrix networks are also shown, along with their braces (cyan carbons). See 
also Figures S1-S5 and Table S1. 
Fig. 2. Alternating access in the ADP/ATP carrier. (A) Surface view of the BKA-inhibited carrier 
(m-state) and (B) of the CATR-inhibited S. cerevisiae Aac2p carrier (c-state, PDB: 4C9H). The 
blue semi-transparent surfaces reveal the internal cavities. The residues of the substrate-
binding site (spheres with green carbons) lie at the center of the membrane and are 
alternately accessible to the mitochondrial matrix (BKA-inhibited carrier) or cytoplasmic 
(CATR-inhibited carrier) sides of the membrane. The BKA-inhibited carrier (C), and CATR-
inhibited carrier (D), viewed from the mitochondrial matrix. The BKA-inhibited carrier (E), and 
the CATR-inhibited carrier (F), viewed from the cytoplasmic side of the membrane. They are 
shown as a surface colored by electrostatic potential (blue, +15 kT e-1; white, neutral; red, -
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15 kT e-1). The positions of the matrix helices are indicated in (C), (D) and (E). See also Figures 
S4 and S5. 
Fig. 3. Cytoplasmic salt bridge network and gate. (A) Cytoplasmic salt bridge network and 
tyrosine braces in the BKA-inhibited carrier, showing polar interactions (black dotted lines) 
with indicated distances (Å). The inset shows interactions in the wild-type carrier. (B) View of 
the cytoplasmic salt bridge network and brace in CATR-inhibited carrier (ScAac2, PDB: 4C9H). 
(A) and (B) are viewed from the cytoplasmic side of the membrane. (C) Mutation of R100 and 
Y204 residues bracing the cytoplasmic network reduces the thermal stability of BKA-inhibited 
carriers. The apparent melting temperature is represented by the mean ± S.D., with n = 6 for 
mutants and n = 12 for wild-type. (D) Schematic diagram illustrating the cytoplasmic (c) and 
matrix (m) networks in TtAac. The circles represent transmembrane helices, with numbers 
indicating the corresponding helices. Polar inter-domain interactions are marked by black 
dashes. (E) The residual transport rates of brace mutants, represented by the mean ± S.D., 
with n = 4. (F) The cytoplasmic gate in the BKA-inhibited carrier. (G) Cytoplasmic gate in the 
CATR-inhibited carrier. (F) and (G) are viewed from the cytoplasmic side of the membrane. 
For (C) and (E), P>0.05, not-significant (NS); P>0.01, *; P>0.0001, ***; P>0.00001, **** by 
two-tailed Student’s t-test. See also Figure S4 and Table S2. 
Fig. 4. Structural basis for inhibition of the ADP/ATP carrier by bongkrekic acid. (A) Structure 
of the inhibitor bongkrekic acid (BKA) with the stereochemistry of chiral centers and double 
bonds labelled. (B) Overview of the inhibitor-binding site. The carrier is shown as a wheat 
cartoon, with BKA in ball-and-stick representation (orange carbon atoms). Amino acid 
residues forming the binding-pocket are shown in stick representation. Amino acids that are 
part of the putative substrate-binding pocket are shown with green carbon atoms. Additional 
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amino acids that form salt bridges or hydrogen bonds, or van der Waals interactions, are 
shown with blue or gray carbon atoms, respectively. (C) Detailed view of the BKA-binding site, 
with salt bridges shown as green dashed lines, and hydrogen bonds as black dashed lines. 
Y89, which forms a hydrogen bond to BKA, has been removed to provide a clearer view. (D) 
Mutations that confer resistance to BKA (Zeman et al., 2003) affect residues that interact or 
are in van der Waals contact with BKA (yellow), but do not affect the putative substrate-
binding site (green). The contact points of the substrate-binding site are indicated by black 
spheres with white Roman numerals. The hydrogen bond between Y89 and BKA is indicated 
by the black dashed line. The spheres indicate the van der Waals radii of the affected residues 
and BKA. See also Figures S4 and S6. 
 
Fig. 5. Role of conserved glycines and residues with small side-chains. (A) Role of conserved 
small amino acids in the intra-domain interface. Domain 1 is highlighted (blue cartoon). 
Equivalent views for (B) domain 2 (yellow) and (C) domain 3 (red). Residues of the GxxxG motif 
and the πxxxπ motif are shown as magenta and green spheres, respectively. (D) Overview of 
residues forming the m-state intra-domain inter-helical interface, viewed from the 
cytoplasmic side of the membrane. (E) Equivalent residues, shown in the c-state (PDB: 4C9H). 
In (D) and (E), the carrier is shown in cartoon representation, with domains colored (domain 
1, blue; domain 2, yellow; domain 3, red). Residues are shown as spheres, colored as in panels 
A-C). See also Figure S4. 
 
Fig. 6. Conformational changes between m- and c-states, and the structural consequences 
of inhibitor-binding. (A) Structure of domain 1 in the m-state (blue cartoon) versus the c-state 
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(PDB: 4C9H, outline). (B) and (C) similar views of domains 2 (m-state yellow cartoon, c-state 
outline) and 3 (m-state red cartoon, c-state outline), respectively. The orange spheres mark 
the positions of the conserved prolines of the signature sequence Px[DE]xx[KR]. The 
numbered black spheres mark the positions of the substrate-binding site contact points 
(Robinson and Kunji, 2006). Domains have been aligned on their core elements. (D) 
Superposition of domains 1 to 3 of CATR-inhibited ScAac2 (PDB:4C9H, colored by domain, as 
in (A)-(C)). The kink at the cytoplasmic-end of H2 is indicated by a blue triangle, and also 
highlighted in (A). The yellow triangle highlights the displacement of H3, also apparent in (B). 
(E) Superposition of domains 1 to 3 of BKA-inhibited TtAac (colored by domain, as in (A)-(C)), 
confirming the conservation of domain structure. (F) Superposition of gate and core elements 
from the BKA-inhibited structure (colored by domain, as in (A)-(C)) and CATR-inhibited 
structure (PDB: 4C9H, colored gray). (G) CATR binding induces a bend of H2 because K108 on 
H2 of ScAac2 (equivalent to R100 in TtAac) interacts electrostatically with the two sulfate 
groups of CATR. Displacement of the cytoplasmic end of H2 induces a similar displacement of 
H3. (H) Superposition of the crystal structure of BKA-inhibited TtAac, (gray cartoon), and the 
uninhibited m-state model (colored by domain as in (A)-(C)). The uninhibited m-state model 
was generated by applying symmetry restraints between the domains, whilst treating them 
as rigid bodies. BKA induces a displacement of the matrix side of domain 1. The cytoplasmic 
side of the carrier is unaffected. (I) Comparison of BKA-inhibited and uninhibited m-state 
models suggests that the domain 1 displacement is due to the steric bulk of the inhibitor, 
combined with electrostatic repulsion between one of the BKA carboxyl groups and E37 on 
H1. Domain 3 has been removed to provide a clearer view of the inhibitor. See also Figures 
S3, S4 and S7. 
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Fig. 7. Proposed transport mechanism of the mitochondrial ADP/ATP carrier. (A) 
Conformational changes between models of the uninhibited c- and m-states viewed laterally 
from the membrane, with helices shown as cylinders. The three-fold pseudosymmetry axis is 
shown as a dotted gray line. Conformational changes between c- and m-states can be 
described as a rotation of the core elements, coupled with an inward movement of the gate 
elements. Core elements 1, 2 and 3 are colored by domain in blue, yellow and red, 
respectively, and the gate elements are colored gray. The asterisk marks the extra turn of α-
helix on the matrix end of H1, seen in fungal ADP/ATP carriers. (B) Conformational changes 
between c- and m-states use the substrate-binding site as a fulcrum. Alignment of models of 
the uninhibited c- (blue) and m-states (red), with lines connecting equivalent Cα positions, 
generated by RAPIDO (Mosca and Schneider, 2008). Substrate-binding site residues are 
shown in green ball-and-sticks. The three-fold pseudosymmetry axis is shown as a dotted gray 
line. (C)-(F) Models of the uninhibited c-state and m-states viewed from the cytoplasmic side 
of the inner mitochondrial membrane, (C) and (D) respectively, and from the mitochondrial 
matrix, (E) and (F) respectively, and are colored and labelled as in (A). Loop regions between 
H2/H3 and H4/H5 have been omitted to provide a clearer view of the core and gate elements. 
(G) Accessibility of the substrate-binding site in the uninhibited carrier models. The carrier is 
shown as a cartoon colored as in (A). The blue semi-transparent surface shows the internal 
cavities. ATP and ADP are shown in sphere representation in different views. See also Movie 
S1. 
 
Supplemental figure titles and legends 
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Fig. S1. Alignment of the amino acid sequences of selected mitochondrial ADP/ATP carriers, 
and representative electron density of the TtAac-Nb complex. Related to Figure 1. (A) 
Alignment of the mitochondrial ADP/ATP carriers from Thermothelomyces thermophila 
(TtAac), from Saccharomyces cerevisiae isoform 2 (ScAac2) and isoform 3 (ScAac3), and 
bovine (BtAAC1) and human (HsAAC1) isoform 1. Amino acids are colored according to their 
properties: basic K, R and H are blue, acidic D and E are red, polar N, Q, S and T are green, 
aliphatic A, I, L, M and V are pink, aromatic F, Y and W are orange, structural G and P are 
magenta, and C is yellow. The negatively charged (red) and positively charged (blue) residues 
of the matrix and cytoplasmic networks are indicated by up and down triangles, respectively. 
The positions of the glutamine brace (Q brace) and tyrosine brace (Y brace) are indicated by 
green and cyan squares, even if they are not conserved in ADP/ATP carriers. The purple and 
lime circles indicate the positions of the GxxxG and πxxxπ motifs. The contact points of the 
substrate binding site are shown in black circles with roman numerals (Robinson and Kunji, 
2006). (B) Stereo-view showing the contents of the asymmetric unit, with the carrier shown 
in rainbow colored ribbon representation, and the nanobody as a wheat ribbon. A PEG 
molecule is shown in ball-and-stick representation, and partially-modelled cardiolipins as 
sticks. The blue mesh shows the final 2mFo-DFc electron density map, contoured at 1 times 
the root mean square electron density, and shown within 5 Å of the atoms. (C) Detailed view 
of the bongkrekic acid-binding site. BKA is shown with orange carbons. Amino acids that are 
part of the putative substrate-binding pocket are shown with green carbon atoms. Additional 
amino acids that form salt bridges or hydrogen bonds, or van der Waals interactions, are 
shown with blue or gray carbon atoms, respectively. The blue mesh shows the final 2mFo-DFc 
electron density map, sharpened by applying a negative B-factor (B=-45 Å2), contoured at 1 
times the root mean square electron density, and shown within 5 Å of the atoms. (D) Detailed 
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view of the cytoplasmic salt bridge network and brace. The blue mesh shows a different view 
of the map in (C). 
 
Fig. S2. Interactions between nanobody and ADP/ATP carrier. Related to Figure 1. (A) Crystal 
packing shows alternating layers of carrier proteins (Aac, gray cartoon, with one molecule 
highlighted as a rainbow cartoon) and nanobodies (Nb, wheat cartoon), with the nanobodies 
playing key roles in forming crystal contacts. (B) In the crystal, each ADP/ATP carrier molecule 
(Aac, gray cartoon) interacts with one nanobody (wheat cartoon, interactions highlighted in 
black box) via the nanobody CDR2 (blue) and CDR3 (red) loops, and with a symmetry-related 
nanobody (violet cartoon, interactions highlighted in blue box). (C) An enlarged view of the 
interactions involving the nanobody CDR2 and 3 loops. The CDR3 loop interacts with the 
matrix end of H1, the matrix helix h12, and the loop connecting them, via hydrogen bond and 
electrostatic interactions (between D56 of the carrier and R99 of the nanobody). (D) An 
enlarged view of the interactions with a symmetry-related nanobody (violet cartoon), with 
A155 and R161 of the carrier forming hydrogen bonds with Q119. These interactions are likely 
to be solely due to crystal packing. 
 
Fig. S3. Bound cardiolipin acts as an inter-domain bridge. Related to Figures 1 and 6. (A) 
Cardiolipin binding sites (ball-and-stick representation, with gray carbon atoms) with cdl802 
highlighted. The protein is shown in surface representation, colored by electrostatic 
potential (blue, +10 kT e-1; white, neutral; red, -10 kT e-1). Cardiolipin phosphates occupy 
pockets with positive electrostatic potential. (B) Detailed view of the binding site for cdl802. 
Cardiolipin phosphate groups form hydrogen bonds with the amide groups at the N-
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terminal ends of the even-numbered and matrix helices, and interact with the positively-
charged ends of the helix dipoles, as seen in the c-state (Ruprecht et al., 2014). The 
cardiolipin molecule is shown in ball-and-sticks. Amino acids making interactions with the 
lipid are shown as thin sticks. Residues in the conserved [YWF][RK]G and [YF]xG motifs are 
shown in purple and green, respectively. Hydrogen bond and electrostatic interactions 
between protein and lipid are shown by cyan dashed lines. The helix dipoles associated with 
the even-numbered and matrix helices are shown (blue, δ+, to red, δ-), and inter-helical 
hydrogen bonds are shown as thin dashed black lines. 
 
Fig. S4. Alignment of symmetry-related triplets from yeast and human carrier sequences. 
Related to Figures 1-3 and 5-6. (A) The odd-numbered helices and (B) even-numbered helices 
of different mitochondrial carriers of S. cerevisiae (Sc), H. sapiens (Hs), M. musculus (Mm), 
and Aspergillus oryzae (Ao). The residues are shown as a triplet of symmetry-related residues 
of domain 1, 2 and 3 together to emphasize the symmetry in the three‐fold repeats of 
mitochondrial carriers (Robinson et al., 2008). Below the triplets are the corresponding 
numbers of the residues in TtAac that form the symmetry-related triplet. Amino acids are 
colored according to their properties as in Fig. S1. Indicated above are the functional elements 
of mitochondrial carriers and the contact points of the substrate binding site in black circles 
with roman numerals (Robinson and Kunji, 2006). Figure adapted from Figs. S1 and S3 from 
(Robinson et al., 2008). 
 
Fig. S5. Transport activity and growth on glycerol of alanine replacements mutants of the 
substrate-binding site residues of TtAac. Related to Figures 1, 2 and 4. (A) Transport assays 
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in fused membrane vesicles of Lactococcus lactis, expressing the wild-type and single 
alanine replacement mutants of TtAac. (B) Drop test on YPG plates of yeast expressing wild-
type and single alanine replacement mutants of TtAac, showing that none of the binding site 
mutants are capable of growing on glycerol. R100A serves as a control. 
 
Fig. S6. Binding of bongkrekic acid and ATP. Related to Figure 4. (A) mFo-DFc polder OMIT 
electron density map for BKA, contoured at 3 times the root mean square electron density, 
shown with the final model. Q93 and Y200, which are in hydrophobic contact with BKA, have 
been removed to provide a clearer view. (B) Schematic drawing of the binding-site, showing 
amino acid residues within 4 Å of BKA. Hydrogen bonds and salt bridges are shown as green 
dashed lines with indicated distances (Å). Red arcs indicate residues in hydrophobic contact 
with the inhibitor, with spokes radiating toward the atoms they contact. Figure generated by 
Ligplot+ (Laskowski and Swindells, 2011). (C) Putative binding mode of ATP. The model was 
generated by docking in AutoDock 4.2 (Forli et al., 2016), treating the protein as a rigid 
molecule and with S238 modelled as an alternative common rotamer. The model shows the 
adenine ring of ATP binding to a hydrophobic pocket formed by residues Y196 (aromatic 
stacking), G192 and I193. S238 may form a hydrogen bond to the adenine ring, and R197 a 
hydrogen bond to the ribose (black dotted lines). The phosphate groups of ATP interact with 
the positively-charged residues K30, R88 and R287 (green dotted lines). The features of this 
binding site mimic those predicted for ADP binding to the c-state (Dehez et al., 2008; Kunji 
and Robinson, 2006; Mifsud et al., 2013; Robinson and Kunji, 2006; Wang and Tajkhorshid, 
2008). (D) View of the BKA binding-site from the matrix side, highlighting residues in the 
putative substrate-binding site (shown in stick representation). Electrostatic interactions 
between these residues and BKA are shown as dotted green lines, and hydrogen bonds as 
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dotted black lines. The view is the same as (C) illustrating the overlap between the BKA and 
ATP-binding site. (E) Mutation of binding-site residues reduces the thermal stability of BKA-
inhibited variants. Residues forming polar interactions with BKA, or proximal to the inhibitor, 
are highlighted in red. (F) Binding-site mutants show increased thermal stability in the 
presence of CATR, hence are folded correctly and able to bind the inhibitor. CATR induces a 
greater stabilization than BKA. Mutation of residues that form salt bridges to CATR (R88, 
R197), or form the binding-pocket (G192, I193, Y196, S238) (Ruprecht et al., 2014), reduces 
the apparent melting temperature of the CATR-inhibited protein. These residues are shown 
with red bars. Mutation of residues distal to CATR (K30, S238) results in a smaller reduction 
in apparent melting temperature. In (E) and (F), the apparent melting temperature is 
represented by the mean ± S.D., with n = 3. P>0.05, not-significant (NS); P>0.01, *; P>0.0001 
, ***; P>0.00001, **** by two-tailed Student’s t-test. 
Fig. S7. Comparison of BKA-inhibited m-state structures from crystals grown with and 
without nanobody. Related to Figure 6. (A) Superposition of m-state carrier structures from 
crystals grown with nanobody (P3221 space group, gray tube) and without nanobody (P212121 
space group, tube with domain 1, blue; domain 2, yellow; domain 3, red), viewed from the 
membrane. The structures superimpose with 0.6 Å RMSD over 1096 atoms, showing that 
presence of the nanobody, different detergent and crystallization conditions, and different 
crystal packings have not perturbed the structure of the BKA-inhibited state. (B) The same 
superposition as (A), viewed from the cytoplasmic side of the membrane. (C) Stereo-view of 
electron density maps for the P212121 crystal form, following molecular replacement (using 
individual domains from the P3221 crystal) and rigid-body refinement in AutoBuster. The 
P3221 structure is shown as a gray cartoon, with the P212121 colored by domain. (D) Electron 
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density for domain 1. (E) Partial density for BKA, not included in the molecular replacement 
search models, gives confidence in the quality of the molecular replacement phases. In (C)-
(E), the 2mFo-DFc electron density map, contoured at 1 times the root mean square electron 
density (σ), is shown as a blue mesh, and the mFo-DFc electron density map is shown 
contoured at +3σ (green mesh) and -3σ (red mesh). 
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STAR Methods 
Contact for reagent and resource sharing 
Further information and requests for resources and reagents should be directed to and will 
be fulfilled by the Lead Contact, Edmund R.S. Kunji (ek@mrc-mbu.cam.ac.uk). 
Experimental model and subject details 
Wild-type ADP/ATP carriers for biophysical and structural studies were expressed in 
Saccharomyces cerevisiae strain WB-12 (MATα ade2-1 trp1-1 ura3-1 can1-100 aac1::LEU2 
aac2::HIS3), and grown in YEPG at 30 °C. Mutant ADP/ATP carriers for biophysical studies 
were expressed in Saccharomyces cerevisiae strain W303-1B (MATα leu2-3,112 trp1-1 can1-
100 ura3-1 ade2-1 his3-11,15), and grown in YEPG + 0.1% glucose at 30 °C. For transport 
assays, wild-type and mutant proteins were expressed in Lactococcus lactis, using the 
expression vector pNZ8048 and a nisin A-inducible promoter, and grown in M17 media 
supplemented with 1% (w/v) glucose and 5 μg/ml chloramphenicol. Nanobodies were 
expressed in E. coli strain WK6 (su-), grown in Terrific Broth at 28 °C to an OD600 of 0.7-1.2 and 
induced with 1 mM isopropyl-β-D-thiogalactoside. 
 
Method Details 
 
Thermostability analysis of wild-type and mutant ADP/ATP carriers 
Wild-type and mutant ADP/ATP carriers were expressed and purified using established 
procedures (King et al., 2016). The gene for the ADP/ATP carrier from Thermothelomyces 
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thermophila (TtAac), encoding residues 8-311, was engineered with an upstream N-terminal 
His8 tag and Factor Xa protease cleavage site, and ligated into a modified pYES3 vector. 
Mutants of TtAac for biophysical characterization were produced by overlap-extension PCR. 
Expression vectors were electroporated into Saccharomyces cerevisiae strain W303-1B. 
Positive transformants were selected on Sc-Trp plates. Cells containing the desired construct 
were grown in 5 L of YEPG + 0.1% glucose at 30 °C for 24 h, or in 50 L of YPG medium in an 
Applikon 140 Pilot System with an eZ controller. Mitochondria were prepared and proteins 
purified as described (King et al., 2016), but with 2% dodecyl-β-D-maltoside (Glycon 
Biochemicals GmbH) being used for solubilization of mitochondria. Thermostability data were 
obtained by using the thiol-reactive fluorophore N-[4-(7-diethylamino-4-methyl-3-
coumarinyl)phenyl] maleimide (CPM) (Alexandrov et al., 2008), as described previously (King 
et al., 2016). 
 
Transport assays of wild-type and mutant ADP/ATP carriers 
For transport assays, wild-type and mutant proteins were expressed in Lactococcus lactis, 
using the expression vector pNZ8048 and a nisin A-inducible promoter. Following expression, 
membranes were isolated and fused with liposomes, and transport rates determined by 
measuring uptake of 14C-labeled ADP. Full details of these methods have been described 
previously (King et al., 2016). 
 
Expression and purification of BKA-inhibited ADP/ATP carriers 
The construct for the thermostabilized (Q302K mutation) ADP/ATP carrier from 
Thermothelomyces thermophila (TtAac), encoding residues 8-311, engineered with an 
upstream N-terminal His8 tag and Factor Xa protease cleavage site, was produced in a 
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modified pYES3 vector as described previously (King et al., 2016). For purification of carrier-
nanobody complexes, a modified construct was produced by PCR, encoding a Q302K 
mutation and MetSer upstream of residues 4-315 of the carrier, but without the His8 tag and 
Factor Xa site. The expression vectors were transformed by electroporation into 
Saccharomyces cerevisiae strain WB-12 (MATα ade2-1 trp1-1 ura3-1 can1-100 aac1::LEU2 
aac2::HIS3) (Hashimoto et al., 1999). Transformants were selected initially on Sc-Trp plates, 
and then on YEPG plates. For large scale fermentations, a 2-L pre-culture was used to 
inoculate 100 L of YEPG medium in an Applikon 140 Pilot System with an eZ controller. Cells 
were grown at 30 °C for 72 h and harvested by centrifugation (4,000g, 20 min, 4 °C). 
Mitochondria were prepared by disrupting cells with a bead mill (Dyno-Mill Multilab, Willy A. 
Bachofen AG Maschinenfabrik, Switzerland), as described (Thangaratnarajah et al., 2014). The 
total mitochondrial protein concentration was adjusted to 20 mg/mL with 0.1M MES pH 6.5, 
10% glycerol. Mitochondria were flash frozen in liquid nitrogen, and stored at -80 °C before 
use. 
 
BKA-inhibited His-tagged TtAac was purified starting from 1 g of mitochondria. Carriers were 
inhibited with 2 nmol bongkrekic acid (BKA, Sigma Aldrich) per mg mitochondrial protein, 
supplemented with 250 μM ADP (50 mL final volume), and two Roche Complete Mini EDTA-
free protease inhibitor tablets at room temperature for 30 min. Subsequent steps were 
performed at 4 °C. Mitochondria were pelleted by centrifugation (48,000g, 15 min, 4 °C), the 
supernatants removed, and the pellets resuspended in an equal volume of 100 mM Tris pH 
7.4, 10% glycerol. Mitochondria were solubilized in 2% decyl maltose neopentyl glycol (10-
MNG, Anatrace) solution, with 20 mM imidazole, 150 mM NaCl, 5 μM BKA and two Roche 
Complete Mini EDTA-free protease inhibitor tablets, in a final volume of 90 mL, for 1 h at 4 
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°C. The solubilizate was clarified by centrifugation (200,000g, 30 min, 4 °C) before loading 
onto a 1-mL Ni Sepharose column (GE Healthcare, High Performance). The column was 
washed with 40 mL of buffer A (10 mM Tris pH 7.4, 150 mM NaCl, 20 mM imidazole, 0.1 
mg/mL tetraoleoyl cardiolipin (Avanti Polar Lipid), 0.02% 10-MNG, 5 μM BKA), followed by 25 
mL of buffer B (10 mM Tris pH 7.4, 50 mM NaCl, 0.05 mg/mL tetraoleoyl cardiolipin, 0.02% 
10-MNG, 10 μM BKA), at a flow rate of 3 mL/min. The Ni Sepharose was recovered as a slurry 
(total volume ≈ 2 mL), supplemented with 10 mM CaCl2 and 60 μg Factor Xa protease (NEB), 
and incubated overnight at 10 °C. The slurry was transferred into empty Proteus 1-Step Batch 
Mini Spin columns (Generon) and the protein was eluted from the resin by centrifugation 
(500g, 5 min, 4 °C). Residual Ni Sepharose was removed by an additional centrifugation step 
(12,000g, 10 min, 4 °C). The protein concentration was determined by BCA (Thermo 
Scientific), using bovine serum albumin as standard. Protein for crystallization experiments 
was concentrated to 2.5 mg/mL using centrifugal concentrators (Amicon Ultra 50 K). 
 
Purification of nanobody targeting BKA-inhibited carrier 
For nanobody generation, one llama (Lama glama) was immunized with BKA-inhibited 
thermostabilized TtAac, which had been reconstituted into 1,2-dioleoyl-sn-glycero-3-
phosphocholine:tetraoleoyl cardiolipin (20:1 g/g ratio, Avanti Polar Lipid) liposomes at a 10:1 
lipid:protein ratio (wt:wt), using established methods (Lee et al., 2015). A phage display library 
of nanobodies was prepared in the pMESy4 vector from peripheral blood lymphocytes as 
described (Pardon et al., 2014). Nanobodies were identified by selecting phages that bound 
to solid-phase immobilized proteoliposomes in the presence of BKA, and confirming lack of 
binding to CATR-inhibited protein reconstituted into proteoliposomes, or to empty 
liposomes. Six nanobody families were identified that specifically bound the BKA-inhibited 
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protein, one of which included the nanobody used for crystallization and structure 
determination (nanobody CA9848). For purification of nanobody-carrier complexes, 
nanobody constructs were modified by introducing a Factor Xa cleavable C-terminal His8 tag 
via PCR. Nanobodies were expressed in the periplasm of E. coli strain WK6 (su-), following 
methods described previously (Pardon et al., 2014). Briefly, 1-L cultures in Terrific Broth were 
grown to an OD600 of 0.7-1.2 and induced with 1 mM isopropyl-β-D-thiogalactoside. Cells 
were harvested after overnight growth at 28 °C, and periplasmic extract prepared using TES 
(Tris EDTA Sucrose) buffer. Nanobodies were purified from the periplasmic extract by Ni-NTA 
(Qiagen) affinity chromatography. 
 
Purification of BKA-inhibited TtAac-Nb complexes 
Mitochondria (500-650 mg total protein) were inhibited with 2 nmol bongkrekic acid (BKA, 
Sigma Aldrich) per mg mitochondrial protein, supplemented with 20 μM ADP (final volume of 
25 mL), at room temperature for 2 h. All subsequent steps were performed at 4 °C. 
Mitochondria were pelleted by centrifugation (48,000g, 15 min, 4 °C), the supernatants were 
removed, and the pellets were resuspended in an equal volume of Tris-buffered saline. 
Mitochondria were solubilized in 2% 10-MNG (Anatrace) solution, with 20 mM imidazole, 150 
mM NaCl, 5 μM BKA and one Roche Complete Mini EDTA-free protease inhibitor tablet, in a 
final volume of 45 mL, for 1 h at 4 °C. The solubilizate was clarified by centrifugation 
(200,000g, 30 min, 4 °C). 3 mg purified His-tagged nanobody was added to the solubilizate 
and incubated for 30 min at 4 °C, before adding Ni Sepharose (GE Healthcare, High 
Performance, 0.5 mL resin) and continuing the incubation overnight. The suspension was 
poured into an empty XK16 column (GE Healthcare) and packed by gravity flow. The column 
was washed with 15.5 mL of buffer C (10 mM Tris pH 7.4, 150 mM NaCl, 20 mM imidazole, 
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0.02 mg/mL tetraoleoyl cardiolipin (Avanti Polar Lipid), 0.35 % HEGA-10 (Anatrace), 5 μM 
BKA), followed by 17 mL of buffer D (10 mM Tris pH 7.4, 150 mM NaCl, 10 mM imidazole, 10 
mM CaCl2, 0.35% HEGA-10, 10 μM BKA), at a flow rate of 0.4 mL/min. The slurry was 
recovered (volume ≈ 1.3 mL), supplemented with 30 μg Factor Xa protease and incubated at 
10 °C for 2 h. The slurry was transferred into empty Proteus 1-Step Batch Mini Spin columns 
(Generon) and protein was eluted from the resin by centrifugation (500g, 5 min, 4 °C). The 
protein was concentrated to a 0.5 mL volume using centrifugal concentrators (Amicon Ultra 
50 K) and applied to a 4-mL Sephadex G75 column (GE Healthcare) packed in an empty PD10 
column (GE Healthcare) and equilibrated with 10 mM Tris pH 7.4, 50 mM NaCl, 0.35% HEGA-
10, 10 μM BKA. The protein was applied and eluted by gravity flow, with the TtAac-Nb 
complex eluting in volume fractions between 0.5-1.5 mL. The protein was concentrated to 
A280 ≈ 8-10 using centrifugal concentrators (Amicon Ultra 50 K) and used in crystallization 
trials. 
 
Crystallization 
Crystals were grown using the sitting drop vapour diffusion technique. Crystallization plates 
were set up with drop ratios of 200 nL protein and 200 nL precipitating solution, or 500 nL of 
protein and 500 nL of precipitating solution, using a Mosquito robot (TTP Labtech). Crystals 
of TtAac were grown at 22 °C using a precipitating solution of 90 mM Hepes pH 7.0, 1.8 % 3-
methyl-3-pentanol, 30% PEG600 and 0.5 mM dodecyl-β-D-maltoside (Glycon Biochemicals 
GmbH). Crystals were harvested from the drops and flash frozen in liquid nitrogen. Crystals 
used for structure determination of the TtAac-Nb complex came from two conditions setup 
at 4 °C, either: 0.1M Hepes pH 7.5, 3% 3-methyl-3-pentanol, 18% PEG400; or 0.1M MES pH 
6.5, 1% 3-methyl-3-pentanol, 22% PEG400. Crystallization plates were incubated at 10 °C, and 
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crystals appeared within 3 days. Crystals were cryo-protected using PFO (Sigma Aldrich) or LV 
(Mitegen) cryo oils, and flash frozen in liquid nitrogen.  
 
Data collection and structure determination 
Diffraction data for the TtAac crystal were collected at 100 K at the European Synchrotron 
Radiation Facility beamline ID23-2 with a Mar 225 CCD detector using a 10 μm microfocus X-
ray beam (0.8729 Å wavelength). Diffraction data for the TtAac-Nb crystals were collected at 
100 K at Diamond Light Source beamline I24 with a Pilatus 6M detector using a 9x6 μm 
microfocus X-ray beam (0.9686 Å wavelength). Data were collected using helical data 
collection methods. Datasets were indexed, integrated, scaled and merged using the 
programs XDS (Kabsch, 2010) and AIMLESS (Evans and Murshudov, 2013), as implemented in 
AutoPROC (Vonrhein et al., 2011). Due to the anisotropic diffraction from the crystals, 
datasets were ellipitically truncated and corrected using STARANISO (Tickle et al., 2018), as 
implemented in AutoPROC. Data collection statistics are shown in Table S1. 
 
Structure determination of the TtAac-Nb complex was initiated using a crystal that diffracted 
anisotropically to 3.9 Å along 0.894 a* - 0.447 b*, 3.9 Å along b* and 3.1 Å along c*. Analysis 
by phenix.xtriage (Adams et al., 2010) showed that the crystal was untwinned. Phases were 
determined by molecular replacement in PHASER (McCoy et al., 2007), by searching 
sequentially with a homology model of the Nb (based on PDB: 5IMK; translation function Z 
score (TFZ) = 8.1, log likelihood gain (LLG) = 43), then with a homology model for domain 1 
(residues 16-45 and 61-90 based on CATR-inhibited Saccharomyces cerevisiae ScAac2, PDB: 
4C9H chain A; TFZ = 10.8, LLG = 113). Domain 2 (residues 116-152 and 165-208 based on PDB: 
4C9H chain A) could be placed by molecular replacement, but it was clear from the electron 
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density maps, and from maps produced after density modification with Parrot (Cowtan, 
2010), that the C-terminal end of H4 was in a different position. This region was rebuilt, and 
molecular replacement with domain 2 repeated (TFZ = 16.6, LLG = 297). At this stage, electron 
density maps allowed the manual placement and rebuilding of domain 3 (residues 226-252 
and 262-294). Density features, such as the extra turn of helix on the matrix side of H1, as 
observed in the yeast c-state structures (Ruprecht et al., 2014), helped to confirm the 
arrangement of domains. Iterative cycles of model building in Coot (Emsley et al., 2010) and 
refinement in Buster (Bricogne et al., 2017) were carried out. B-factor sharpened maps were 
used to help confirm side-chain positions. Refinement with Buster used LSSR restraints and 
grouped B-factors (2 per residue, for main chain and side chain). In the early stages of model 
building and refinement, LSSR restraints were from the nanobody homology model, and a 
carrier homology model based upon PDB: 4C9H chain A. In later stages, LSSR restraints were 
based on models of the TtAac-Nb complex that had been refined with phenix.refine (Afonine 
et al., 2012) using secondary structure restraints. B-factor refinement included TLS 
parameterization (1 TLS group per chain). Diffraction data were collected from a crystal 
diffracting to higher resolution (statistics in Table S1), also untwinned, and model building 
and refinement were continued using these data, maintaining the flagged reflections from 
the earlier dataset for calculating Rfree. BKA was modelled into positive mFo-DFc difference 
electron density present in the central cavity. Several factors were considered during the 
modelling of BKA: (1) the stereochemistry of the ligand, combined with minimal geometrical 
distortions following refinement, (2) minimal clashes with protein residues, (3) maximal 
number of protein-ligand interactions, (4) maximal cross-correlation with the 2mFo-DFc 
density map. Refinement statistics are shown in Table S1. The final model consists of residues 
11-252 and 257-306 of TtAac, residues 1 to 124 of the nanobody, a molecule of BKA and of 
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PEG, and partially modelled cardiolipins in the asymmetric unit. The cardiolipin between 
domains 2 and 3 has good density. However, density for cardiolipins between domains 1 and 
2 and domains 1 and 3 is of poorer quality, due to the BKA-induced displacement of domain 
1 making it impossible for cardiolipins to bridge the distance between the even-numbered 
transmembrane and matrix helices. Both these cardiolipins have been modelled as partial 
lipids at both positions. It is likely that these cardiolipins interact predominantly with either 
the even-numbered transmembrane or matrix helix, stochastically throughout the crystal. 
Residues M250-S252 and K257 of the carrier lie in very weak electron density in this crystal, 
but their position is supported by good density in the earlier crystal. 
 
Phases for the TtAac structure (without nanobody) were determined by molecular 
replacement with PHASER (McCoy et al., 2007), searching with carrier domains from the 
TtAac-Nb model (domain 1: residues 13-107, domain 2: residues 116-211, and domain 3: 220-
306; TFZ= 17.2, LLG= 378). Rigid-body refinement was carried out in Buster (Bricogne et al., 
2017), with each domain defined as a rigid-body, reaching R=36.2%, Rfree=37.1%. The resulting 
electron density maps showed density for features not included in the model (loop regions, 
BKA and cardiolipin phosphates, Fig. S7). The carrier structure superposes very well with that 
solved from the TtAac-Nb crystals (RMSD of 0.6 Å over 1096 matched atoms). Splitting domain 
1 into smaller rigid sub-domains, or performing jelly-body refinement in REFMAC, did not 
change the structure. 
 
Comparisons of the TtAac BKA-inhibited m-state structure with the ScAac2 CATR-inhibited c-
state shown in the figures used PDB: 4C9H chain A. The program HOLLOW 
(http://hollow.sourceforge.net) was used to generate the blue semi-transparent surfaces 
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shown in figures 2A, 2B and 7G. Protein structure figures were generated in PyMOL. The 
polder OMIT map (Liebschner et al., 2017) for BKA was calculated after perturbing the TtAac-
Nb model by removing the BKA coordinates and subjecting the model to coordinate and 
group B-factor refinement in phenix.refine. The coordinates of BKA were added back prior to 
polder map calculation, to define the region for bulk solvent exclusion whilst being excluded 
from map calculation. 
 
Models of the uninhibited c- and m-states 
The model of the uninhibited c-state of TtAac was generated by superposing the core and 
gate elements from the BKA-inhibited TtAac structure onto the structure of CATR-inhibited 
ScAac2p (PDB: 4C9H chain A) in PyMOL. Superposition of the backbones of core domains 1 
and 3, and of even-numbered helices 4 and 6 could be accomplished without outlier rejection. 
Superposition of the backbones of core domain 2 and even-numbered helix 2 required outlier 
rejection and refinement, as implemented in the align command. As discussed in the 
manuscript, these differences are attributable to CATR-induced protein distortions. The 
superposed elements of the TtAac crystal structure provided an initial model for the 
uninhibited c-state, which was completed by loop building based upon the available crystal 
structures. The structure was energy-minimized in Chimera (Pettersen et al., 2004), rotamer 
outliers were corrected in PyMOL, and the geometry was checked by Molprobity (Chen et al., 
2010). 
 
To create a model of the uninhibited m-state of TtAac, the structure of the BKA-inhibited 
carrier was initially symmetrized using Modeller 9.19 (Sali and Blundell, 1993), applying a 
symmetry restraint with weight 2 between the Cα atoms of domains 1 and 2 and between 
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the Cα atoms of the respective symmetry-related residues of domains 2 and 3. 
Symmetrization corrected the displacement of domain 1, resulting in domain 1/domain 2 and 
domain 1/domain 3 interfaces with suitable geometry for cardiolipin-binding. The 
symmetrised models were used as a template for placing the domains from the crystal 
structure, treating the domains as rigid bodies. This provided an initial model for the 
uninhibited m-state, which was completed by loop building based upon the available crystal 
structures. The geometry was checked by Molprobity (Chen et al., 2010), rotamer outliers 
were corrected in PyMOL, and the structure was energy-minimized in UCSF Chimera 
(Pettersen et al., 2004) to reduce clashes. 
 
The models of the uninhibited states were aligned using RAPIDO (Mosca and Schneider, 
2008), prior to generating a morph in Chimera (Pettersen et al., 2004). 
 
Quantification and statistical analyses 
For CPM-based thermostability analysis, the apparent melting temperature was calculated 
from the first derivative of the thermal denaturation profile, and represented by the average 
and standard deviation of three technical repeats (Fig. S6E and F) or six repeats (n=3 with two 
biological repeats, for Fig. 3C). Significance was assessed by a two-tailed Student’s t-test 
assuming equal variance, with P values indicated as follows: P>0.05, not-significant (NS); 
P>0.01, *; P>0.001, **; P>0.0001, ***; P>0.00001, ****. The null hypothesis is that the 
mutation has no effect upon the melting temperature of the BKA-inhibited protein. 
 
For the transport studies, the residual transport rate is represented by the average and 
standard deviation of four technical repeats, with each mutant having its own wild-type 
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comparison (Figs. 3E and S5A). Significance was assessed by a two-tailed Student’s t-test 
assuming unequal variance, with P values indicated as follows: P>0.05, not-significant (NS); 
P>0.01, *; P>0.001, **; P>0.0001, ***; P>0.00001, ****. The null hypothesis is that the 
mutation has no effect upon the transport rate. 
 
Data and software availability 
Coordinates, structure factor amplitudes and Fourier map coefficients for the nanobody-
bound BKA-inhibited mitochondrial ADP/ATP carrier (TtAac-Nb) have been deposited in the 
Protein Data Bank under accession number PDB: 6GCI. The structure factor file includes 
structure factors for the P212121 TtAac crystal as a second data block. CPM and transport assay 
data have been deposited as a Mendeley dataset (doi:10.17632/x4xdfh6gt2.1). 
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Supplemental item titles 
Movie S1. Conformational changes of the mitochondrial ADP/ATP carrier between c- and 
m-states. Related to Figure 7. This movie illustrates a morph between models of the 
uninhibited c-state and m-state. The domains of the carrier are colored separately: domain 1 
(blue), domain 2 (yellow), domain 3 (red). The morph illustrates the conformational transition 
between c-state, with the central cavity open to the mitochondrial intermembrane space, and 
m-state, with the cavity open to the matrix side. The transition between states proceeds via 
an occluded state, in which the central substrate-binding site is inaccessible from either side 
of the membrane. Residues of the GxxxG motif, the πxxxπ motif and the cytoplasmic gate are 
shown as spheres scaled to van der Waals radii with magenta, green and orange carbons, 
respectively. Key functional elements are shown in ball-and-stick representation: substrate-
binding site (green carbons) and matrix and cytoplasmic salt bridge networks (blue carbons 
for positively-charged residues, red carbons for negatively-charged residues). The lipid bilayer 
shown at the start of the video is a POPC lipid bilayer from 
https://heller.userweb.mwn.de/membrane (Heller et al., 1993). 
 
 
 KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Bacterial and Virus Strains  
E. coli strain WK6 (su-) ATCC ATCC 
number:47078 
Lactococcus lactis strain NZ9000 MoBiTec GmbH Cat# VS-
ELS09000-01 
Chemicals, Peptides, and Recombinant Proteins 
Dodecyl-β-D-maltoside Glycon 
Biochemicals GmbH 
Cat#D97002 
Decyl maltose neopentyl glycol (10-MNG) Anatrace Cat#NG322 
HEGA-10  Anatrace Cat#H110 
N-[4-(7-diethylamino-4-methyl-3-
coumarinyl)phenyl] maleimide (CPM) 
Sigma Aldrich Cat#C1484 
Bongkrekic acid (BKA) Sigma Aldrich Cat#B6179 
Complete Mini EDTA-free protease inhibitor tablets Roche Cat#05056489001  
Nickel Sepharose (High Performance) GE Healthcare Cat#17526802 
Nickel-NTA Superflow Qiagen Cat#30430 
Sephadex G75 GE Healthcare Cat#17005001 
Factor Xa protease NEB Cat#P8010L 
Tetraoleoyl cardiolipin (TOCL) Avanti Polar Lipid Cat#710335  
 
1,2-dioleoyl-sn-glycero-3-phosphocholine Avanti Polar Lipid Cat#850375  
PFO cryo oil Sigma Aldrich Cat#317926 
LV cryo oil Mitegen Cat#LVCO-1 
Critical Commercial Assays 
Bicinchoninic acid (BCA) Protein assay kit ThermoFisher 
Scientific 
Cat#23227 
Deposited Data 
Structure of yeast mitochondrial ADP/ATP carrier 
isoform 2 inhibited by carboxyatractyloside 
(Ruprecht et al., 
2014) 
PDB: 4C9H 
Nanobody targeting human Vsig4 in Spacegroup 
C2 
(Wen et al., 2017) PDB: 5IMK 
BKA-inhibited TtAac-Nb complex structure This paper PDB: 6GCI 
CPM and transport data This paper doi:10.17632/x4xdf
h6gt2.1 
Experimental Models: Organisms/Strains 
Saccharomyces cerevisiae W303-1B ATCC ATCC 
number:201238 
Saccharomyces cerevisiae WB-12 (Hashimoto et al., 
1999) 
A gift from Dr H. 
Terada, Tokyo 
University of 
Science 
N/A 
Oligonucleotides 
See Table S2 This paper N/A 
Recombinant DNA 
Key Resource Table
Modified pYES3 vector (Bamber et al., 
2006; King et al., 
2016) 
pYES-pMIR2-
AAC2 
pNZ8048 vector  
N.B. pNZ8148 is a commercially available updated 
version of this vector 
MoBiTec GmbH Cat# VS-
ELV00200-01 
 
pMESy4 vector GenBank KF415192.1 
Software and Algorithms 
XDS (Kabsch, 2010) http://xds.mpimf-
heidelberg.mpg.de 
AIMLESS (Evans and 
Murshudov, 2013), 
http://www.ccp4.ac
.uk/html/aimless.ht
ml 
AutoPROC (Vonrhein et al., 
2011) 
http://www.globalp
hasing.com/autopr
oc/ 
STARANISO  (Tickle et al., 2018) http://www.globalp
hasing.com/starani
so/manual/ 
Phenix (Adams et al., 2010) http://www.phenix-
online.org 
PHASER  (McCoy et al., 2007) http://www.phaser.
cimr.cam.ac.uk/ind
ex.php/Phaser_Cr
ystallographic_Soft
ware 
Parrot (Cowtan, 2010) http://www.ccp4.ac
.uk/html/parrot.htm
l 
Coot (Emsley et al., 2010) https://www2.mrc-
lmb.cam.ac.uk/per
sonal/pemsley/coo
t/ 
Buster (Smart et al., 2012) http://www.globalp
hasing.com/buster/ 
Hollow  http://hollow.sourc
eforge.net 
PyMOL Schrödinger https://pymol.org/2/ 
Molprobity (Chen et al., 2010) http://molprobity.bi
ochem.duke.edu 
UCSF Chimera (Pettersen et al., 
2004) 
https://www.cgl.uc
sf.edu/chimera/ 
Modeller 9.19 (Sali and Blundell, 
1993) 
https://salilab.org/
modeller/ 
Other 
Proteus 1-Step Batch Mini Spin columns Generon Cat#GEN-1SBM-
40 
PD10 column GE Healthcare Cat#17043501 
Amicon Ultra 50K centrifugal concentrators Merck Millipore Ltd. Cat#UFC505024 
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Table S1. Data collection, refinement and validation statistics. Related to STAR methods. 
 TtAac-Nb complex† TtAac‡ 
Data collection*   
Space group P3221 P212121 
Cell dimensions   
   a, b, c (Å) 75.65, 75.65, 295.48 76.59, 77.26, 96.54 
   a, b, g  (°)  90.0, 90.0, 120.0 90.0, 90.0, 90.0 
Resolution (Å) 29.35-3.30 (3.43-3.30) 96.54-3.85 (4.24-3.85) 
Rmerge 0.063 (0.688) 0.103 (0.960) 
I / sI 12.1 (2.3) 9.1 (1.4) 
Completeness (spherical, %) 85.1 (40.3) 56.9 (13.6) 
Completeness (ellipsoidal, %) 91.9 (88.8) 88.5 (73.2) 
Redundancy 
CC(1/2) 
4.7 (4.7) 
1.000 (0.823) 
3.5 (3.5) 
0.999 (0.558) 
   
Refinement   
Resolution (Å) 29.35-3.30  
No. reflections work set/test set 13203/628  
Rwork/Rfree (Buster) 25.2/28.3  
No. atoms   
    Protein 3064  
    Ligand/ion 182  
    Water 0  
Mean B-factors (Å2)   
    Protein 110.8  
    BKA/CDL/PEG 80.4/136.4/89.6  
R.m.s. deviations   
    Bond lengths (Å) 0.008  
    Bond angles (°) 
Ramachandran favoured (%) 
Ramachandran outliers (%) 
Molprobity score 
0.87 
96.8 
0.0 
1.47 
 
*Values in parentheses are for highest-resolution shell. 
†Diffraction data collected from one crystal, which diffracted anisotropically to 3.51 Å along 
0.894 a*- 0.447 b*, 3.51 Å along b* and 3.04 Å along c*. 
‡Diffraction data collected from one crystal, which diffracted anisotropically to 3.61 Å along 
a*, 5.6 Å along b*, and 4.4 Å along c*. 
  
Supplemental Tables
 Table S2. DNA oligonucleotide sequences. Related to STAR methods. 
Oligonucleotide Sequence 5’-3’ 
TtAac no tag 
forward 
CATGACATGTCTAAACAAGAAACTAAAATTTTAGGAATGCCACCCTTCGTG 
TtAac no tag 
reverse 
CTAGCTCGAGCTATCATTAACCAGATCCACCTTTAAAAGCTTTGCCGAATA
GTAGAATTTGC 
Nb Xa-His8 
forward 
TCACAAGCTTAAGGAGACAGTACA 
Nb Xa-His8 
reverse 
CTAGTCCGGATTATTAATGGTGATGGTGATGGTGGTGATGTTCGCTGGTC
GCGGTACGACCTTCGATCGCACGGTCTGAGGAGACGGTGACCTG 
Q302K reverse CTCGAGTCTAGATCATTTGCCGAATAGTAGAATTTTCAATTGATCGTATAT
GGACAACAC 
K30A forward CTGCAGCAGTTAGTGCTACAGCTGC 
K30A reverse GCAGCTGTAGCACTAACTGCTGCAG 
R88A forward GCCAACGTTATAGCTTATTTTCCAACCCAG 
R88A reverse CTGGGTTGGAAAATAAGCTATAACGTTGGC 
N96A forward TCCAACCCAGGCATTGGCTTTTGCTTTTAG 
N96A reverse CTAAAAGCAAAAGCCAATGCCTGGGTTGGA 
R100A forward GAACTTTGCTTTTGCTGATAAGTTTAAGGC 
R100A reverse GCCTTAAACTTATCAGCAAAAGCAAAGTTC 
G192A forward GGTCCATCCGTGGCCGCTATTGTTGTTTACAGA 
G192A reverse TCTGTAAACAACAATAGCGGCCACGGATGGACC 
 Oligonucleotide Sequence 5’-3’ 
TtAac no tag 
forward 
CATGACATGTCTAAACAAGAAACTAAAATTTTAGGAATGCCACCCTTCGTG 
TtAac no tag 
reverse 
CTAGCTCGAGCTATCATTAACCAGATCCACCTTTAAAAGCTTTGCCGAATA
GTAGAATTTGC 
Nb Xa-His8 
forward 
TCACAAGCTTAAGGAGACAGTACA 
Nb Xa-His8 
reverse 
CTAGTCCGGATTATTAATGGTGATGGTGATGGTGGTGATGTTCGCTGGTC
GCGGTACGACCTTCGATCGCACGGTCTGAGGAGACGGTGACCTG 
Q302K reverse CTCGAGTCTAGATCATTTGCCGAATAGTAGAATTTTCAATTGATCGTATAT
GGACAACAC 
K30A forward CTGCAGCAGTTAGTGCTACAGCTGC 
K30A reverse GCAGCTGTAGCACTAACTGCTGCAG 
R88A forward GCCAACGTTATAGCTTATTTTCCAACCCAG 
R88A reverse CTGGGTTGGAAAATAAGCTATAACGTTGGC 
N96A forward TCCAACCCAGGCATTGGCTTTTGCTTTTAG 
N96A reverse CTAAAAGCAAAAGCCAATGCCTGGGTTGGA 
R100A forward GAACTTTGCTTTTGCTGATAAGTTTAAGGC 
R100A reverse GCCTTAAACTTATCAGCAAAAGCAAAGTTC 
G192A forward GGTCCATCCGTGGCCGCTATTGTTGTTTACAGA 
G192A reverse TCTGTAAACAACAATAGCGGCCACGGATGGACC 
I193A forward CCATCCGTGGCCGGTGCTGTTGTTTACAGAGGT 
I193A reverse ACCTCTGTAAACAACAGCACCGGCCACGGATGG 
BA
C D
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